Evidence map›Paper›PMID 42360010›Full record

ReviewBioMed research international2026

Exploring the Therapeutic Potential of Nobiletin in Nonsmall Cell Lung Cancer.

Adam Haysom-McDowell, Jack Bartholomew, Stewart Yeung, Keshav Raj Paudel, Nenad Naumovski, Dennis Chang, Hui Chen, Parteek Prasher, Brian Gregory George Oliver, Frederick Williams and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adam Haysom-McDowellDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales, Australia, uts.edu.au.ORCID https://orcid.org/0009-0007-6899-2252
Jack BartholomewDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales, Australia, uts.edu.au.
Stewart YeungDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales, Australia, uts.edu.au.ORCID https://orcid.org/0009-0000-2771-9988
Keshav Raj PaudelWoolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia, mq.edu.au.ORCID https://orcid.org/0000-0002-3591-2080
Nenad NaumovskiFood, Chemical and Biotechnology Cluster, Singapore Institute of Technology, Punggol, Singapore, singaporetech.edu.sg.ORCID https://orcid.org/0000-0002-2841-4497
Dennis ChangNICM Health Research Institute and School of Science, Western Sydney University, Westmead, New South Wales, Australia, westernsydney.edu.au.ORCID https://orcid.org/0000-0002-6584-738X
Hui ChenSchool of Life Science, University of Technology Sydney, Ultimo, New South Wales, Australia, uts.edu.au.ORCID https://orcid.org/0000-0001-6883-3752
Parteek PrasherDepartment of Chemistry, University of Petroleum and Energy Studies, Dehradun, India, upes.ac.in.ORCID https://orcid.org/0000-0002-9412-9424
Brian Gregory George OliverWoolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia, mq.edu.au.ORCID https://orcid.org/0000-0002-7122-9262
Frederick WilliamsDepartment of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, Ohio, USA, utoledo.edu.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales, Australia, uts.edu.au.ORCID https://orcid.org/0000-0002-7507-1159
Gabriele De RubisDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales, Australia, uts.edu.au.ORCID https://orcid.org/0000-0001-7088-396X

Funding

Council of Australasian University LibrariansUniversity of Technology Sydney
6 · The paper itself

Abstract

Nonsmall cell lung cancer (NSCLC) is one of the most prevalent cancers and leading causes of cancer-related mortality worldwide. Despite advancements in medical treatment, current therapeutic strategies are often hindered by late-stage diagnosis, high recurrence rates and resistance to therapies. These challenges highlight the urgent need for novel, less toxic and more effective treatment options. Phytoceuticals, bioactive plant-derived compounds, have gained increasing attention for their potential to complement or enhance conventional cancer therapies. Among these, nobiletin, a polymethoxylated flavonoid found in citrus peels, has promising anti-inflammatory, antioxidant and anticancer properties. This review explores the therapeutic potential of nobiletin in NSCLC, focusing on its ability to modulate key cancer hallmarks such as uncontrolled proliferation, metastasis, immune evasion and multidrug resistance. Preclinical studies suggest that nobiletin inhibits tumour growth, enhances chemosensitivity and suppresses metastasis through multiple pathways. However, its clinical application is currently limited by poor bioavailability, prompting the need for innovative delivery strategies. Therefore, this review also discusses emerging approaches to improve nobiletin's biological activity, supporting further investigations into its role in NSCLC therapy.

Indexed as

Carcinoma, Non-Small-Cell LungFlavonesLung NeoplasmsAnimalsAntioxidantsHumansAntioxidantsFlavonesnobiletinnobiletinnonsmall cell lung cancerphytoceuticalpulmonarytherapeutic

Identifiers

PMID42360010
PMCPMC13307195

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.